Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$184.90
-1.5%
$192.70
$134.13
$212.71
$291.14B0.262.08 million shs1.03 million shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.99
-0.3%
$95.14
$79.52
$124.00
$23.32B1.36947,309 shs646,501 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.74
-0.8%
$27.01
$22.09
$28.75
$147.96B0.3537.21 million shs24.05 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+1.72%+1.48%-7.24%-8.22%+38.59%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-1.53%-3.18%-4.62%-12.79%-2.40%
Pfizer Inc. stock logo
PFE
Pfizer
+0.28%-2.09%-5.01%-5.50%+13.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$184.90
-1.5%
$192.70
$134.13
$212.71
$291.14B0.262.08 million shs1.03 million shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.99
-0.3%
$95.14
$79.52
$124.00
$23.32B1.36947,309 shs646,501 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.74
-0.8%
$27.01
$22.09
$28.75
$147.96B0.3537.21 million shs24.05 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+1.72%+1.48%-7.24%-8.22%+38.59%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-1.53%-3.18%-4.62%-12.79%-2.40%
Pfizer Inc. stock logo
PFE
Pfizer
+0.28%-2.09%-5.01%-5.50%+13.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.85
Moderate Buy$205.3311.05% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.72
Moderate Buy$130.6041.97% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.8412.05% Upside

Current Analyst Ratings Breakdown

Latest PFE, BNTX, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/14/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/13/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/12/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$155.00 ➝ $140.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$171.00 ➝ $158.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$150.00 ➝ $140.00
5/4/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingSell
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.88$12.73 per share14.52$30.55 per share6.05
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.17$1.33 per share69.08$86.54 per share1.06
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.34$4.36 per share5.90$15.86 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6627.7616.011.5417.19%30.86%12.68%7/27/2026 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.659.00N/A11.83%19.44%8.41%N/A

Latest PFE, BNTX, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million
4/29/2026Q1 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.52$2.58+$0.06$0.9850$14.93 billion$15.29 billion
2/14/2026Q4 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/A-$0.3870N/A-$1.47N/A$1.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.35%+2.30%65.17%N/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.68%-13.20%131.30%16 Years

Latest PFE, BNTX, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.52
0.91
0.71
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff (PFE)
...
Pfizer's Turnaround Is Taking Shape
4 stocks to watch on Wednesday: BABA, PFE, TWO, NBIS
Top Analyst Reports for Meta, Pfizer & Salesforce
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$184.90 -2.82 (-1.50%)
Closing price 03:59 PM Eastern
Extended Trading
$185.22 +0.32 (+0.17%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$91.99 -0.24 (-0.26%)
Closing price 04:00 PM Eastern
Extended Trading
$92.00 +0.01 (+0.01%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Pfizer stock logo

Pfizer NYSE:PFE

$25.74 -0.22 (-0.85%)
Closing price 03:59 PM Eastern
Extended Trading
$25.78 +0.04 (+0.14%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.